Semaglutide Medicine 07 December 2022 Extended indication Extension of indication to include treatment of adolescents for weight management for Wegovy. Therapeutic value No estimate possible yet Total cost Registration phase Registration application pending Product Active substance Semaglutide Domain Metabolism and Endocrinology Reason of inclusion Indication extension IND Main indication Other metabolism and Endocrinology Extended indication Extension of indication to include treatment of adolescents for weight management for Wegovy. Current proprietary name Already available biosimilars / generics Proprietary name Wegovy Manufacturer Novo Nordisk Portfolio holder Mechanism of action GLP-1 receptor agonist Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP No Submission date September 2022 Expected Registration July 2023 Orphan drug No Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Average 68 week / weeks Frequency of administration 1 times a week Dosage per administration 2,4 mg References Weghuber et al 2022 NEJM Additional remarks In combinatie met leefstijl interventie. De behandelduur was de maximale behandelduur in de studie. Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks